# SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC

> **NCT04106180** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 63 (estimated)

## Conditions studied

- NSCLC Stage IV

## Interventions

- **DRUG:** GM-CSF
- **DRUG:** Sintilimab
- **RADIATION:** SBRT

## Key facts

- **NCT ID:** NCT04106180
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-30
- **Primary completion:** 2022-08-31
- **Final completion:** 2023-08-31
- **Target enrollment:** 63 (ESTIMATED)
- **Last updated:** 2019-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04106180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04106180, "SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04106180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*